CTOs on the Move

Storandt Pann Margolis

www.spmadvertising.com

 
Storandt Pann Margolis is a La Grange, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Wellmont Health System

Founded in 1996, Wellmont Health System is the premier healthcare provider in Northeast Tennessee and Southwest Virginia.

Columbine Health Systems

Columbine Health Systems is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Columbine Health Systems is based in Loveland, CO. You can find more information on Columbine Health Systems at www.columbinehealth.com

Metamark

Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.

The Tech Group Subsidiary of West Pharmaceutical Services

The Tech Group, Inc Subsidiary of West Pharmaceutical Services, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The Tech Group, Inc Subsidiary of West Pharmaceutical Services, Inc. is based in Scottsdale, AZ. You can find more information on The Tech Group, Inc Subsidiary of West Pharmaceutical Services, Inc. at www.techgroup.com

MSI

MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).